## **2020 Impact Report & Financial Review**
**Antibiotic** RESEARCH UK
##
|ONTENTS||
|---|---|
|Antibiotic Resistance and Us|4|
|Sharon’s Story|5|
|Science and Research|6|
|Patient Support|7|
|Education|8|
|Fundraising|9|
|Plans for the Future|10|
|A Big ‘Thank You’|11|
|2020 Financial Statements|12-28|
**----- Start of picture text -----**
ADMINISTRATIVE INFO
**----- End of picture text -----**
## **Registered charity name:**
## **Antibiotic** RESEARCH UK
**----- Start of picture text -----**
GET IN TOUCH
**----- End of picture text -----**
**FIGHTING ANTIBIOTIC RESISTANCE TODAY AND TOMORROW**
Antibiotic Research UK Genesis 5 Church Lane Heslington York YO10 5DQ
## T: 01904 468719
E: info@antibioticresearch.org.uk
**----- Start of picture text -----**
PRESS ENQUIRIES
**----- End of picture text -----**
Please contact
## T: +44 (0)1904 468719
E: media@antibioticresearch.org.uk
**----- Start of picture text -----**
FIND US ONLINE
**----- End of picture text -----**
## **www.antibioticresearch.org.uk**
Antibiotic Research UK - Developing New Antibiotics
## **Registered charity number:**
1157884
@1ANTRUK
AntibioticResearchUK
## **Other names:**
ANTRUK
Antibiotic Research UK
## **“**
_The year 2020 will be remembered as an annus horribilis for the world. Despite the tragedy and disruption, we have continued to fight for the future of modern medicine. One silver lining is the way the pandemic shone a light on the importance and value of scientists and researchers._
_It has been a frightening time for people with drug-resistant infections. We still don’t know how many lives will have been lost to secondary bacterial infections at this point._
_We did not have time to lament the expense of paused labresearch programmes, as the people we support needed us more than ever. We established ourselves as a trusted source of information and extended our patient support service to help as many people as possible._
_I was delighted to welcome Simon Dukes as our Trustee Chair Designate during this time, bringing a wealth of experience from the Civil Service and the Pharmaceutical Services Negotiating Committee._
_Despite the cessation of all face-to-face fundraising activities, we were relieved to maintain a comparable income with 2019. We received our first National Lottery grant and ran a fantastic BBC Radio 4 Appeal. This is testament to each and every person, business and organisation that supported us in 2020, as well as our fantastic team of innovative fundraisers who pivoted to virtual fundraising with enthusiasm._
_Stay safe and please help us save the world from what just might be the next pandemic._
**Professor Colin Garner, Chief Executive.**
## **Antibiotic resistance and us**
Antibiotics are a miracle of modern medicine. They kill bacteria that would otherwise cause severe and often fatal infections. Antibiotics are what make operations, chemotherapy, childbirth and dental work safe.
Tragically, we haven’t looked after our antibiotics, and new variants of bacteria are finding ways to resist them. Increasingly difficult-to-treat infections are arising, and new antibiotics are not easy to develop.
**The World Health Organisation predicts that by 2050, more than 10 million people will die from antibiotic-resistant infections each year.**
But it wasn’t until 2020, and COVID-19, that we saw what millions of deaths from an infectious disease might look like. Our greatest hope as a charity is that scientists, the general public and policymakers will see the parallels between the viral pandemic of 2020 and the ever-growing risk of a bacterial pandemic in the near future, and that they will act now.
Our role remains the same, but with renewed vigour. Antibiotic Research UK exists to save the future of antibiotics - the future of modern medicine. We will do so by investing in research and educating people about this issue. We also stand side by side with those affected by antibiotic-resistant infections, providing support and advice, and helping them campaign for meaningful change.
**The work and the impact you read about on these pages is entirely down to people like you. Thank you.**
4
## **Meet Sharon**
Sharon is no stranger to medical issues, having survived three heart attacks in her 30s, among other things. She lives with her three teenagers and her husband, who have been a real source of support during 2020, especially as she is considered ‘high risk’ and has had to isolate.
In 2019, Sharon experienced a rapid deterioration in her health when she developed sinusitis, a bacterial urinary tract infection and then sepsis and septicaemia (caused by the infection) within a short space of time. She had had sepsis before; this time, however, during her treatment with oxygen and intravenous antibiotics, a clinician told her that she had ESBL _E. coli_ , and they moved her to her own isolated room.
“You can feel the life draining out of your body.”
“Sepsis, caused by a bacterial infection in my case, makes you feel like you are dying. You can feel the life draining out of your body. It was scary to spend three weeks alone in intensive care without any idea why.”
Sharon was given antibiotics that are saved for the most serious and difficult to treat bacterial infections. But when she eventually returned home to continue her recovery, she still hadn’t been given any answers.
“What does ESBL mean? Why did I have to isolate - can I pass it on to my kids? Will I end up in hospital again?”
She also struggled with the after-effects of sepsis itself:
“I found it very hard to get back to being myself again. I hardly laughed, I no longer enjoyed jokes and I lost my enjoyment in things I had liked.”
Feeling let down by the lack of information from medical professionals, Sharon called Arlene, our Patient Support Officer (see page 7), who was able to provide her with some of the answers she was seeking, and a listening ear.
“I was lucky to be able to isolate during the pandemic with my three teenagers and my husband, and to know that Arlene was just a call away if I needed her. I’ve learned to live with most of the fear, but I hope that my story - and Arlene’s support - will help others to feel less afraid and alone.”
**Sharon, and others just like her, are the reason why we strive every day to save our antibiotics, educate people about drug resistance and provide support to people affected by resistant infections.**
5
## **Science and research**
## **Our aims**
We are tackling drug-resistant infections through research by:
1. Breaking the mechanisms by which bacteria resist the effect of antibiotics
2. Identifying new treatments that we can use instead of precious antibiotics
3. Continuing to provide funding for our Small Research Grants/Career Development Awards programme to support academic researchers across the UK working in the field
This year, we saw how science can fight back against infectious diseases. Without the work of scientists, there would be no hope of an end to the pandemic. That is why it’s so important for us to continue to support research into drug-resistant infections; it just might help prevent the next pandemic.
Our pioneering Small Research Grant programme continued to support leading scientists at British academic institutions. Findings from our 2018 grantfunded projects were shared at virtual conferences throughout 2020, and published in leading journals such as the _Archives of Disease in Childhood and Preventive Veterinary Medicine_ .
Thanks to the generosity of our funders, during this year the Trustees allocated £200,000 to be spent via our 2021 research grants. We also prepared for the publication of the results of the DIAMOND trial, a pilot clinical trial conducted in China on a non-antibiotic treatment for infections. The trial demonstrated the feasibility of this type of study, and paves the way for larger trials in the future.
We continued to support work investigating a combination of antibiotic and resistance-breaking medications. UK hospitals have agreed to participate, using bacteria from patients, which we sincerely hope will progress to clinical trials.
**Your funding is what makes this research possible. Thank you.**
## **Patient Support**
Arlene, our fantastic Patient Support Officer, helped over 100 people like Sharon in 2020.
Arlene and our network of volunteers have been speaking at conferences (2020 BioInfect), symposia (NESTA UTI Challenge) and on podcasts (The Steward) to help raise awareness of the human cost of the spread of antibiotic resistance.
We also welcomed a second member to our Patient Support Team, launched a closed community on Facebook for peer-to-peer support and trialed Zoom group calls.
While the solution to the problem will likely be discovered in a lab and administered in hospitals, the impact of antibiotic resistance is felt inside homes around the world. That side of the story is the reason for all our hard work, and it’s one we shone a spotlight on through our collection of real-life stories.
“The unwelcome arrival of COVID-19 has led to calls about symptoms lasting weeks, to discuss fears about developing secondary bacterial infections, or having an ongoing chronic condition including infection and fear that contracting COVID-19 might cause severe illness”.
_Arlene Brailey, Patient Support Officer._
“I have talked to Arlene quite a few times - she’s so kind and understanding. I struggled to get the medical appointments I needed during the pandemic. I have learned to become my own doctor and to listen to my body, but having someone to talk to who understands without judging has been a lifeline. I talk to her about everything - my health, but also my life.”
Sharon (page 5)
Our Patient Support Team has also been busy producing resources to help people learn more about specific antibiotic-resistant infections and their treatments. Nearly 20,000 website visitors used those resources in 2020.
7
## **Education**
**----- Start of picture text -----**
Nted by
**----- End of picture text -----**
## **Spreading the word about antibiotic resistance**
## **SOCIAL MEDIA**
**----- Start of picture text -----**
facebook
4,000 1,300
Twitter Facebook
followers followers
**----- End of picture text -----**
## **THE WEBSITE**
**----- Start of picture text -----**
45,000
nearly
views of our page
200,000 about common
users infections
(a 200% increase on
the previous year)
7,000
25,000 views of our Ask
views of our first article ANTRUK feature
about COVID-19,
bacterial infections
and antibiotic We were approaching our
resistance one-millionth lifetime page
view at the end of the year!
**----- End of picture text -----**
## **Here’s what we produced in 2020:**
- Don’t Dare To Share campaign, about sexually transmitted infections. _Covered on regional radio and TV and in magazines._
- Advances In Antimicrobial Optimisation, our first ever online lecture, watched by 70 academics, clinicians and members of the public. _By Professor Alison Holmes, Imperial College London._
- Our inaugural Great University Science Quiz, encouraging AMR Societies across the UK. _Also raising £2,000 and featuring celebrity scientist quizmasters._
- Diagnosing Antibiotic Allergies leaflet. _Based on the Grampian Health Board’s leaflet, with kind permission._
## **Here’s what we collaborated on:**
- We contributed to Manchester University’s online course about antibiotic resistance, completed by 1,500 people in 85 countries.
- We contributed to Pfizer’s ‘Change The Course’ campaign for World Antimicrobial Resistance Awareness Week.
- Dr Roger Harrison (a member of our Education Committee) also led a successful bid to Manchester Wellcome Institutional Strategic Support Fund, to support science students working with communities to provide education on antibiotic resistance.
8
## **Fundraising**
There’s no doubt about it, 2020 was a very challenging year. But instead of telling you about all of the tea parties, marathons, charity pub quizzes and everything else that was cancelled, we want to shout about the creative ways that our supporters raised money instead.
We were delighted to retain the support of most of our existing Trust and Foundation supporters, and to welcome funding from 15 new ones, too. In total, we raised more than £256,000 from Trusts and Foundations. Thank you!
No marathon? No problem! Our 2.6 challenge inspired people to get involved, including:
- Hector the half-marathon hero (31 half marathons in as many days!)
- Our Head of Fundraising, Alison, leading by example and walking a marathon up and down her own street
- Members of The University of Manchester AMR Society also ran the virtual Purple Wave (part of a rescheduled, virtual Great Manchester Run).
We have missed our Great British Tea Parties, especially during World Antimicrobial Resistance Awareness Week, but did you hear us on Radio 4?! Our BBC Radio 4 Appeal, presented by BBC Inside Science’s Dr Adam Rutherford raised a spectacular £57,000.
And our supporters really got into the spirit of Christmas, hitting our Big Give Christmas Challenge ‘double your donation’ campaign target of £18,000.
What’s more, we’ve learned a thing or two about online/individual fundraising challenges.
- Our inaugural Great University Science Quiz raised over £2,000
- At-home fundraising and sporting activities raised £40,000
- Our supporters have really made the most of it, too! From Cliff, setting himself a wellbeing photography challenge to Chris and his Grateful Dead fan club, we’ve been impressed with a diverse range of digital fundraising efforts.
The York Voluntary Group were supported by very generous donations from those invited to their cancelled National Railway Museum fundraiser, which managed to raise £20,000 without even happening!
We were over the moon to receive our first ever National Lottery award from The National Lottery Community Fund Scotland Awards for All and funding from the Coronavirus Community Support Fund, also distributed by The National Lottery Community Fund (England). Thank you to the Government, and of course to National Lottery players! The grand total of £35,136 was a vital lifeline for our online information and support services at this time.
## **Together, we raised £445,648 under some of the most difficult circumstances imaginable.**
**9**
## **Plans for the future**
## **Preventing the next pandemic**
We are naturally looking to the future with a great deal of hope after a very challenging year. The tail end of this pandemic provides us with an opportunity to raise awareness of the fact that the next one could be caused by antibiotic-resistant infections, unless we all play our part.
The suspension of some academic lab work in 2020 means that there is a huge pent up demand for research funding. During 2020 we agreed to set aside £200,000 for Small Research Grants/Career Development Awards programme to fund UK academics; we look forward to allocating those funds where they will have the most impact soon.
From a fundraising perspective, World AMR Awareness Week will be back with a bang with tea parties and more. We’re thrilled to be continuing our Great University Science Quiz after our successful inaugural event, and we are developing a dedicated student area on our website to further nurture and tap into the enthusiasm and potential of the UK student community. Of course, sporting events are also returning and we have places for both the Vitality Big Half Marathon and the Virgin Money London Marathon.
We will work hard to expand our Patient Support offering to provide more help to those that need it. As well as continuing to provide support and information to people affected by antibiotic-resistant infections, we will also continue to share their stories.
It is so important to show the world that anybody can be affected by these infections, so we must all work together to help overcome them. As well as giving
our supporters a voice, we will raise awareness of our charity and the work we do through strategic media campaigns.
We hope that we have showcased our ability to adapt in the face of great adversity, thanks to our fantastically supportive donors and our ever-creative fundraisers. We will continue to apply determination and innovation in all aspects of our work.
**Most importantly, we will continue to nurture and cherish the partnerships that allow Antibiotic Research UK to achieve much, much more than we would on our own. Thank you for being a part of something so important. Together, we will save modern medicine.**
10
## **A big thank you!**
Thank you to our wonderful supporters for your continued support, and thank you to The Sir James Reckitt Charity, Sylvia Waddilove Foundation and other Trusts and Foundations who supported our vital work in 2020. A special mention to those who made our Radio 4 appeal such a success. We really couldn’t carry out our vital work without you. And of course, a huge thank you to everyone who works for the charity in a paid or voluntary capacity.
Fundraisers:
**Take one simple action today to help protect your loved ones’ futures**
Over 700,000 people die from drug-resistant infections every year. It is predicted that we will reach 10 million annual deaths by 2050 if we don't act now. We are the first charity in the world dedicated to fighting antibiotic resistance, but we can’t do it without you.
By taking action today and remembering Antibiotic Research UK in your Will, you are ensuring that we will be here to continue fighting for the next generation - and the ones after that, too.
**If you would like to speak to someone about leaving a gift in your Will, however big or small, please contact our Legacy fundraiser, Kate Fordham.**
**Email: kate.fordham@antibioticresearch.org.uk Telephone: 07914 324181**
- Ladies’ Section of the Pikes Hill Golf Club in York chose Antibiotic Research UK as Charity of the Year raised more than £1,300 before COVID-19 put a stop to things - and we are thrilled that they are continuing to support us in 2021.
- BBC Radio 4 appeal.
- The National Lottery Community Fund Scotland Awards for All.
- The National Lottery Community Fund Coronavirus Community Support Fund distributed by The National Lottery Community Fund. Thanks to the Government for making this possible.
11
## **Report of the Board of Trustees**
The trustees present their report and the financial statements of the charity for the year ended 31 December 2020. The trustees have adopted the provisions of the Statement of Recommended Practice (SORP) “Accounting and Reporting by Charities” in preparing the annual report and financial statements of the charity.
The financial statements have been prepared in accordance with the accounting policies set out in notes to the accounts and comply with the charity’s governing document, the Charities Act 2011 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland published in October 2019.
**----- Start of picture text -----**
OBJECTIVES & ACTIVITIES
**----- End of picture text -----**
Antibiotic Research UK aims to protect and promote the health of the public, in particular by sponsoring research into the diagnosis, treatment and cure of antibiotic-resistant bacterial infectious diseases, ensuring responsible and sustainable development and deployment of the findings of such research, and raising awareness through public-facing activities and the promotion of networks to share experience of such matters.
Antibiotic Research UK was created by a group of internationally recognised scientists and clinicians expert in antibiotic resistance in 2014. The experts were drawn from a network of representatives from fourteen of the United Kingdom’s top universities as well as from specialty pharmaceutical companies and organisations. Antibiotic Research UK has set itself ambitious goals of developing one new antibiotic therapy by the early 2020’s with subsequent therapies coming on-stream over the next decades.
**----- Start of picture text -----**
PUBLIC BENEFIT
**----- End of picture text -----**
The trustees have due regard to the Charity Commission’s guidance on public benefit, and ensure that the activities of the organisation meet those requirements.
**----- Start of picture text -----**
ACHIEVEMENT AND PERFORMANCE
**----- End of picture text -----**
Included in the impact report.
12
~~ANTIBIOTIC RESEARCH UK~~
**----- Start of picture text -----**
FINANCIAL REVIEW
**----- End of picture text -----**
The consolidated gross income for the year was £445,648 (2019: £420,809). This year’s income figure includes donated services of £51,502 (2019: £58,454).
The consolidated net movement in funds for the year was £96,225 (2019: £41,882), an increase of 130%.
## **Reserves policy**
The year-end level of free reserves was £142,825 (2019: £126,558). The trustees aim to maintain a minimum of free reserves equal to 6 months core expenditure and funds over this sum will be used to fund the charity’s objects.
**----- Start of picture text -----**
STRUCTURE, GOVERNANCE & MANAGEMENT
**----- End of picture text -----**
Antibiotic Research UK is a registered charitable incorporated organisation as of 16 July 2014 and is governed by its constitution, which was amended and approved at the 2016 AGM on 24 October 2016 and at the 2019 AGM on 24 October 2019.
## **Trustees recruitment and appointment**
Trustees are appointed and re-elected in accordance with the provisions set out in the constitution. There should be a minimum of three trustees and a maximum of twelve.
The trustees will retire from office after a full term (3 years) at the next annual general meeting. Any trustee at the AGM 24 October 2019 were deemed to have commenced their first three-year term on that date. A trustee can seek re-election for a further term of office but not a third term without an interval of a year.
Trustees can only be formally appointed as a trustee at the annual general meeting although a person can attend meetings as an observer prior to this point.
## **Trustees induction and training**
The charity trustees will make available to each new charity trustee, on or before his or her first appointment; a copy of the constitution and any amendments made to it; and a copy of the CIO’s latest trustees’ annual report and statement of accounts.
**----- Start of picture text -----**
PLANS FOR FUTURE PERIODS
**----- End of picture text -----**
Included in the impact report.
~~ANTIBIOTIC RESEARCH UK~~
13
## **Report of the Board of Trustees**
**----- Start of picture text -----**
OUR TRUSTEES
**----- End of picture text -----**
Mr N Stalbow Interim chair (until 1 January 2021) Mr J A Farmer Treasurer Professor C Bond Dr R Bowden (Resigned November 2020) Professor C Dowson Ms E Lyon Ms Y Thakurdas (Resigned 1 January 2021)
## **Observer**
Mr S Dukes Chair designate (from 1 January 2021) Mr A Burgess Founding chairman
**Chief Executive** Professor R C Garner
## **Patron**
The Most Revd & Rt Hon the Lord Archbishop of York, J Sentamu (to June 2020)
**----- Start of picture text -----**
ADVISORS
**----- End of picture text -----**
## **Principal Bankers:**
## **Independent Examiner:**
Lloyds Bank PLC 2 Pavement York YO1 9UP
Mr N Clemit ACA, FCCA JWPCreers LLP Chartered Accountants Genesis 5 Church Lane Heslington York YO10 5DQ
~~ANTIBIOTIC RESEARCH UK~~
14
## **Report of the Board of Trustees**
**----- Start of picture text -----**
TRUSTEES RESPONSIBILITIES IN RELATION TO THE FINANCIAL STATEMENTS
**----- End of picture text -----**
The trustees are responsible for preparing the Report of the Board of Trustees’ and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).
The law applicable to charities in England & Wales requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of income and expenditure of the charity for that period. In preparing these financial statements, the trustees are required to:
- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP 2019 (FRS 102);
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.
The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the constitution. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
The trustees are responsible for the maintenance and integrity of the charity and financial information included on the charity’s website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.
Approved by the trustees on 16/07/2021 and signed on their behalf by:
Mr N Stalbow - Trustee
~~ANTIBIOTIC RESEARCH UK~~
15
## **Independent examiner’s report to the Trustees**
I report to the charity trustees on my examination of the accounts of the charity for the year ended 31 December 2020 which comprise the statement of financial activities, balance sheet and relevant notes.
**----- Start of picture text -----**
RESPONSIBILITIES AND BASIS OF REPORT
**----- End of picture text -----**
As the charity’s trustees you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 (“the Act”).
I report in respect of my examination of the charity’s accounts carried out under section 145 of the Act and in carrying out my examination I have followed all the applicable directions given by the Charity Commission under section 145(5)(b) of the Act.
**----- Start of picture text -----**
INDEPENDENT EXAMINER’S STATEMENT
**----- End of picture text -----**
Since the charity’s gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the Act. I confirm that I am qualified to undertake the examination because I am a member of ACCA.
I have completed my examination. I confirm that no material matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:
accounting records were not kept in respect of the charity as required by section 130 of the Act; or
the accounts do not accord with those records; or
- the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a ‘true and fair view’ which is not a matter considered as part of an independent examination.
I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.
## Mr N Clemit
16/07/2021
Mr N Clemit ACA, FCCA
JWPCreers, LLP Chartered Accountants
Genesis 5, Church Lane, Heslington, York, YO10 5DQ
~~ANTIBIOTIC RESEARCH UK~~
16
## **Consolidated statement of financial activities for the year ended 31 December 2020**
**----- Start of picture text -----**
Notes 2020 2020 2020 2019
Unrestricted Restricted Total Total
funds (£) funds (£) funds (£) funds (£)
**----- End of picture text -----**
|Donations and legacies:
Donations and grants
2
Charitable activities
Other trading activities:
Membership fees
Fundraising events
Other interest
**Total income**
Raising funds
3
Charitable activities
4
**Total expenditure**
**Net income/(expenditure)**
Transfer between funds
8,9
Corporation tax receivable
**Net movement in funds**
**Fund balance brought forward at**
**1 January 2019**
**Fund balance carried forward at**
**31 December 2020**
8,9
INCOME
EXPENDITURE|140,470
91,299
1,701
41,811
15
275,296
78,611
275,056
353,667
**(78,371)**
91,115
4,244
**16,988**
131,543
148,531|-
170,352
-
-
-
170,352
-
-
-
**170,352**
(91,115)
-
**79,237**
254,130
333,367|140,470
261,651
1,701
41,811
15
445,648
78,611
275,056
353,667
**91,981**
-
4,244
**96,225**
385,673
481,898|153,732
236,100
556
30,421
-|
|---|---|---|---|---|
|||||420,809|
|||||98,834
283,970|
|||||382,804|
|||||**38,005**
-
3,877|
|||||**41,882**
343,791|
|||||385,673|
All income and expenditure derive from continuing activities.
~~ANTIBIOTIC RESEARCH UK~~
17
## **Balance Sheets as at 31 December 2020**
**----- Start of picture text -----**
Notes Consolidated Charity only
2020 2019 2020 2019
(£) (£) (£) (£)
**----- End of picture text -----**
||**2020**
**(£)**|**2019**
**(£)**|**2020**
**(£)**|**2019**
**(£)**|
|---|---|---|---|---|
|Investments
5
Debtors and prepayments
6
Cash at bank and in hand
Amounts falling due within 1 year
7
Unrestricted funds
Restricted funds
FIXED ASSETS
CURRENT ASSETS
LIABILITIES
NET CURRENT ASSETS
NET ASSETS
THE FUNDS OF THE CHARITY
TOTAL CHARITY FUNDS|-
17,970
483,366
501,336
(19,438)
481,898
481,898
148,531
333,367
481,898|-
20,957
383,074
404,031
(18,358)
385,673
385,673
131,543
254,130
385,673|1
12,172
480,453
492,625
(16,433)
476,192
476,193
142,826
333,367
476,193|1
14,447
381,211|
|||||395,658
(14,971)
380,687|
|||||380,688|
|||||126,559
254,129|
|||||380,688|
Approved by the trustees on 16/07/2021 and signed on their behalf by:
Mr J A Farmer
Mr J A Farmer - Treasurer
18
~~ANTIBIOTIC RESEARCH UK~~
**Notes to the consolidated accounts for the year ended 31 December 2020**
**----- Start of picture text -----**
1. ACCOUNTING POLICIES
**----- End of picture text -----**
## **Basis of Accounting**
Antibiotic Research UK – Developing New Antibiotics is a charitable incorporated organisation in England. The address of the registered office is given in the charity information within the trustees’ report of these financial statements.
The charity constitutes a public benefit entity as defined by FRS 102. The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland issued in October 2019, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102), the Charities Act 2011, and UK Generally Accepted Accounting Practice.
The financial statements have been prepared to give a ‘true and fair’ view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a ‘true and fair view’. This departure has involved following the Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland issued in October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.
The financial statements are prepared on a going concern basis under the historical cost convention, modified to include certain items at fair value. The financial statements are prepared in sterling which is the functional currency of the charity.
The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated.
## **Group financial statements**
These financial statements consolidate the results of the charity and its wholly owned subsidiary ANTRUK Enterprises Limited on a line by line basis.
The gross income of the charity for the year was £445,633 and the result of the charity for the year was net income of £95,505.
~~ANTIBIOTIC RESEARCH UK~~
19
**Notes to the consolidated accounts for the year ended 31 December 2020**
## **Fund accounting**
Unrestricted funds are funds which are available for use at the discretion of the trustees in furtherance of the general objectives of the charity.
Restricted funds are donations which the donor has specified are to be solely used for particular areas of the charity’s work or for specific projects being undertaken by the charity.
## **Income**
All income is included in the statement of financial activities when the charity is legally entitled to the income and the amount can be quantified with reasonable accuracy.
Donated services are accounted for at a reasonable estimate of their value to the charity and are included in the statement of financial activities as income when receivable.
## **Expenditure**
All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category.
Raising funds relates to costs incurred directly to generate donations. Charitable expenditure comprises those costs incurred by the charity in pursuit of its charitable object. Grants payable are charged in the year when the offer is conveyed to the recipient.
## **Tangible fixed assets and depreciation**
Individual fixed assets costing £500 or more are capitalised at cost. Currently Antibiotic Research UK has no tangible fixed assets.
## **Debtors**
Trade and other debtors are recognised at the settlement amount due. Prepayments are valued at the amount net of any trade discounts due.
## **Cash at bank and in hand**
Cash at bank and cash in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.
20
~~ANTIBIOTIC RESEARCH UK~~
**Notes to the consolidated accounts for the year ended 31 December 2020**
## **Creditors and provisions**
Creditors and provisions are recognised where the charity has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount.
## **Financial instruments**
The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.
|Donations
Gift aid
Online giving
Donated services
**2. DONATIONS & GRANTS**|||
|---|---|---|
||**2020 Unrestricted**
**& Total funds (£)**|**2019 Unrestricted**
**& Total funds (£)**|
||52,248
15,969
20,751
~~51,502~~
140,470|60,557
10,181
24,540
58,454|
|||153,732|
Donated services are legal services provided pro bono by Ashurst LLP, London and professional services by Costello Medical.
|Fundraiser fees
Fundraising expenses
**3. RAISING FUNDS EXPENDITURE**|||
|---|---|---|
||**2020 Unrestricted**
**& Total funds (£)**|**2019 Unrestricted**
**& Total funds (£)**|
||76,154
2,457
78,611|76,515
22,319|
|||98,834|
~~ANTIBIOTIC RESEARCH UK~~
21
## **Notes to the consolidated accounts for the year ended 31 December 2020**
**----- Start of picture text -----**
Unrestricted Restricted funds 2020 Total funds 2019 Unrestricted
Notes funds (£) (£) (£) & Total funds (£)
4. CHARITABLE ACTIVITIES
**----- End of picture text -----**
|**Notes**
**4. CHARITABLE ACTIVITIES**|**Unrestricted**
**funds (£)**|**Restricted funds**
**(£)**|**2020 Total funds**
**(£)**|**2019 Unrestricted**
**& Total funds (£)**|
|---|---|---|---|---|
|Trading subsidiary
5
Legal and professional fees
Consultancy fees
Accountancy
Printing, postage and stationery
Website and IT
Phone and internet
Computer and software
Insurance
Travel and subsistence
Subscriptions
Bank and CAF charges
Sundry expenses
~~Trustee expenses~~
Recruitment costs|114,318
100,705
31,261
9,570
3,009
12,031
144
461
522
886
-
1,496
-
-
653
275,056|-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-|114,318
100,705
31,261
9,570
3,009
12,031
144
461
522
886
-
1,496
-
-
653
275,056|112,630
106,904
30,229
8,485
7,450
8,031
473
1,574
522
4,513
117
1,211
111
362
1,358|
|||||283,970|
~~ANTIBIOTIC RESEARCH UK~~
22
**Notes to the consolidated accounts for the year ended 31 December 2020**
**----- Start of picture text -----**
5. TRADING SUBSIDIARY
**----- End of picture text -----**
The wholly owned trading subsidiary, ANTRUK Enterprises Ltd (company number: 10396024), which was incorporated in England and Wales on 27 September 2016, provides funding to research projects concerning antibiotics. The charity owns the entire issued share capital of 1 ordinary share of £1. A summary of the trading results is shown below. Monies are granted from the charity to the trading subsidiary to fund research projects.
**----- Start of picture text -----**
2020 (£) 2019 (£)
SUMMARY PROFIT & LOSS ACCOUNT
**----- End of picture text -----**
|**SUMMARY PROFIT & LOSS ACCOUNT**|**2020 (£)**|**2019 (£)**|
|---|---|---|
|Research costs and administration expenses
Income from group undertakings
Corporation tax receivable
Other interest
Retained in subsidiary
Current assets
Creditors: amounts falling due within one year
Total net assets
Aggregate share capital and reserves
THE ASSETS AND LIABILITIES OF THE SUBSIDIARY WERE:|(114,317)
110,780
4,244
15
722
8,711
(3,004)
5,707
5,707|(112,630)
112,899
3,877
-|
|||4,146|
|||8,373
(3,388)|
|||4,985|
|||4,985|
**----- Start of picture text -----**
2020 Group 2019 Group 2020 Charity 2019 Charity
(£) (£) (£) (£)
6. DEBTORS
**----- End of picture text -----**
|**6. DEBTORS**|**2020 Group**
**(£)**|**2019 Group**
**(£)**|**2020 Charity**
**(£)**|**2019 Charity**
**(£)**|
|---|---|---|---|---|
|Other debtors
Prepayments and accrued income
VAT
Corporation tax|2,000
10,172
1,554
4,244
17,970|13,000
1,447
2,648
3,862
20,957|2,000
10,172
-
-
12,172|13,000
1,447
-
-|
|||||14,447|
~~ANTIBIOTIC RESEARCH UK~~
23
**Notes to the consolidated accounts for the year ended 31 December 2020**
|**At 1.1.20**
**(£)**
Antibiotic Resistance Breakers
62,879
Patient Support
8,120
Combined Research 2019
58,756
Test Discs
57,186
Combined Research 2019
including Test Discs
67,189
Garfeld Weston Foundation
-
Hobson Charity Ltd
-
Mutate Trial
-
Big Give 2020 programmes
-
Combined Research 2020
including mutate trial
-
Combined Research 2020
including mutate trial &
non-antibiotic alternatives
-
TNL Scotland
-
TNL England
-
254,130
**8. RESTRICTED FUNDS 2020**
**2020 Group**
**(£)**
Accruals
19,438
19,438
**7. CREDITORS DUE WITHIN ONE YEAR**|**At 1.1.20**
**(£)**
Antibiotic Resistance Breakers
62,879
Patient Support
8,120
Combined Research 2019
58,756
Test Discs
57,186
Combined Research 2019
including Test Discs
67,189
Garfeld Weston Foundation
-
Hobson Charity Ltd
-
Mutate Trial
-
Big Give 2020 programmes
-
Combined Research 2020
including mutate trial
-
Combined Research 2020
including mutate trial &
non-antibiotic alternatives
-
TNL Scotland
-
TNL England
-
254,130
**8. RESTRICTED FUNDS 2020**
**2020 Group**
**(£)**
Accruals
19,438
19,438
**7. CREDITORS DUE WITHIN ONE YEAR**|**At 1.1.20**
**(£)**
Antibiotic Resistance Breakers
62,879
Patient Support
8,120
Combined Research 2019
58,756
Test Discs
57,186
Combined Research 2019
including Test Discs
67,189
Garfeld Weston Foundation
-
Hobson Charity Ltd
-
Mutate Trial
-
Big Give 2020 programmes
-
Combined Research 2020
including mutate trial
-
Combined Research 2020
including mutate trial &
non-antibiotic alternatives
-
TNL Scotland
-
TNL England
-
254,130
**8. RESTRICTED FUNDS 2020**
**2020 Group**
**(£)**
Accruals
19,438
19,438
**7. CREDITORS DUE WITHIN ONE YEAR**|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|||**2020 Group**
**(£)**||**2019 Group**
**(£)**||**2020 Charity**
**(£)**|||**2019 Charity**
**(£)**||
|||19,438
19,438||18,358
18,358||||16,433
16,433||14,971|
|||||||||||14,971|
||||||||||||
||||||||||||
||||||**2020**||||||
||||||||||||
|||**At 1.1.20**
**(£)**||**Income**
**(£)**|**Expenditure**
**(£)**|||**Transfer**
**(£)**||**At 31.12.20**
**(£)**|
|||62,879
8,120
58,756
57,186
67,189
-
-
-
-
-
-
-
-
254,130||6,000
4,190
20,700
9,200
1,838
25,000
5,000
23,920
18,075
184
23,920
3,220
29,105
170,352|-
-
-
-
-
-
-
-
-
-
-
-
-
-|||-
(12,310)
(24,426)
(2,117)
(6,203)
-
(5,000)
(23,920)
-
(184)
(4,871)
(1,203)
(10,881)
(91,115)||68,879
-
55,030
64,269
62,824
25,000
-
-
18,075
-
19,049
2,017
18,224|
|||||||||||333,367|
24
~~ANTIBIOTIC RESEARCH UK~~
**Notes to the consolidated accounts for the year ended 31 December 2020**
**Antibiotic Resistance Breakers** (ARB) fund represents monies donated to fund the research into ARBs, this incorporates the Holbeck Charitable Trust funding as it was for the same cause.
**Patient Support** fund represents monies donated to fund a patient support officer whose role will be to develop a portfolio of patient support resources for people affected by antimicrobial resistance.
**Combined Research 2019** fund represents monies donated towards a specific application for funds from Antibiotics Research that identified expenditure across three programmes. Research into new antibiotic therapies, research into non-antibiotic alternatives (Diamond), and a small research grants scheme.
**Test Discs** funds represents monies donated towards the next stage of research. The manufacture and circulation to partners of a test disc sensitivity kit for further testing.
**Combined Research 2019 Including Test Discs** fund represents monies donated towards both of the above two funds.
**Garfield Weston Foundation** fund represents monies donated towards the small research grants programmes.
**Hobson Charity Ltd** fund represents monies donated specifically for purchase of equipment.
**Mutate Trial** fund represents monies donated for the next phase of the MUTATE research programme which is working with hospital microbiology labs in a round robin evaluation of cefepime / sulbactam test discs.
**Big Give 2020 Combined Projects** fund represents monies donated through the online platform Big Give. Antibiotic Research identified the expenditure would cover patient support, original antibiotic resistance breakers and the small grants programmes.
**Combined Research 2020 Including Mutate Trial** fund represents monies donated towards a specific application for funds from Antibiotics Research that identified expenditure across three programmes. Antibiotic resistance breakers, recruitment of more microbiology labs to the MUTATE project and small grants research.
**Combined Research 2020 Including Mutate Trial & Non-Antibiotic Alternatives** fund represents monies donated to the above 2020 combination and includes expenditure on Non-Antibiotic alternatives.
**TNL Scotland** fund represents a National Lottery Award, monies donated are to be used to give Scottish Support Network for People Affected by antibiotic resistant infections in Aberdeen.
**TNL England** fund represents Coronavirus Community Support Fund grant from the National Lottery, monies donated are to be used for national support network for people affected by antibiotic resistant infections in England.
The transfers represent the money spent in ANTRUK Enterprises Ltd on these projects.
~~ANTIBIOTIC RESEARCH UK~~
25
## **Notes to the consolidated accounts for the year ended 31 December 2020**
|Antibiotic Resistance Breakers
Patient Support
Combined Research Programmes
Test Discs
Combined Research Including Test Discs
**RESTRICTED FUNDS 2019**||||||||
|---|---|---|---|---|---|---|---|
|||||**2019**||||
|||||||||
|||**At 1.1.19**
**(£)**|**Income**
**(£)**|**Expenditure**
**(£)**||**Transfer**
**(£)**|**At 31.12.19**
**(£)**|
|||57,379
26,358
92,995
-
-
176,732|6,000
4,587
29,801
65,045
73,514
178,947|-
-
-
-
-
-||(500)
(22,825)
(64,040)
(7,859)
(6,325)
(101,549)|62,879
8,120
58,756
57,186
67,189|
||||||||254,130|
## **9. UNRESTRICTED FUNDS 2020**
|**9. UNRESTRIC**||||**2020**|**2020**||||
|---|---|---|---|---|---|---|---|---|
||||||||||
|||**At 1.1.20**
**(£)**|**Income**
**(£)**|**Expenditure**
**(£)**|**Transfer**
**(£)**||**Tax**
**(£)**|**At 31.12.20**
**(£)**|
|General unrestricted funds
Non-charitable trading funds||126,558
4,985
131,543|275,281
15
275,296|(239,349)
(114,318)
(353,667)|(19,665)
110,780
91,115||-
4,244
4,244|142,825
5,706|
|||||||||148,531|
|General unrestricted funds
Non-charitable trading funds
**UNRESTRICTED FUNDS 2019**|General unrestricted funds
Non-charitable trading funds
**UNRESTRICTED FUNDS 2019**||||||||
|---|---|---|---|---|---|---|---|---|
|||||**2019**|||||
||||||||||
|||**At 1.1.19**
**(£)**|**Income**
**(£)**|**Expenditure**
**(£)**|**Transfer**
**(£)**||**Tax**
**(£)**|**At 31.12.19**
**(£)**|
|||166,220
839
167,059|183,408
-
183,408|(211,720)
(112,630)
(324,350)|(11,350)
112,899
101,549||-
3,877
3,877|126,558
4,985|
|||||||||131,543|
The transfers in both years represents the funds (both restricted for the projects and unrestricted for general expenses) transferred into ANTRUK Enterprises Limited.
26
~~ANTIBIOTIC RESEARCH UK~~
**Notes to the consolidated accounts for the year ended 31 December 2020**
|Fund balances at 31 December 2020 are represented by:
**GROUP**
Current assets
Creditors: amounts falling due in less than one year
Total net assets
**CHARITY**
Investments
Current assets
Creditors: amounts falling due in less than one year
Total net assets
Fund balances at 31 December 2019 are represented by:
**GROUP**
Current assets
Creditors: amounts falling due in less than one year
Total net assets
**CHARITY**
Investments
Current assets
Creditors: amounts falling due in less than one year
Total net assets
**10. ANALYSIS OF NET ASSETS BETWEEN FUNDS**
**ANALYSIS OF NET ASSETS BETWEEN FUNDS**||||||
|---|---|---|---|---|---|
||||**2020**|||
|||||||
|||**Unrestricted**
**funds (£)**|**Restricted**
**funds (£)**||**Total**
**(£)**|
|||167,969
(19,438)
148,531
1
159,258
(16,433)
142,826|333,367
-
333,367
-
333,367
-
333,367||501,336
(19,438)|
||||||481,898|
|||||||
||||||1
492,625
(16,433)|
||||||476,193|
|||||||
||||**2019**|||
|||||||
|||**Unrestricted**
**funds (£)**|**Restricted**
**funds (£)**||**Total**
**(£)**|
|||149,901
(18,358)
131,543
1
141,529
(14,971)
126,559|254,130
-
254,130
-
254,129
-
254,129||404,031
(18,358)|
||||||385,673|
|||||||
||||||1
395,658
(14,971)|
||||||380,688|
~~ANTIBIOTIC RESEARCH UK~~
27
**Notes to the consolidated accounts for the year ended 31 December 2020**
**----- Start of picture text -----**
11. TRUSTEES’ REMUNERATION & EXPENSES
**----- End of picture text -----**
No remuneration was paid or payable directly or indirectly out of the funds of the charity for the period to any trustee or to any person or persons known to be connected with any of them for acting as a trustee.
No trustees were reimbursed expenses (2019: 3 trustees amounting to £412).
**----- Start of picture text -----**
12. RELATED PARTY TRANSACTIONS
**----- End of picture text -----**
Garner Consulting Services received £31,261 (2019: £30,229) for consultancy services. Also received was £31,261 (2019: £30,229) for research project management costs from ANTRUK Enterprises Ltd. As ANTRUK Enterprises Ltd is VAT registered the net cost was £26,051. The total cost to the group was £ 57,312 (2019: £55,419). Professor C Garner (Chief Executive of Antibiotic Research UK) and his wife are the partners in Garner Consulting Services. Of this amount £5,210 was owed to Garner Consulting Services at the year end (2019: £5,210).
Garbutt and Elliott LLP of which J A Farmer is a partner received £6,200 for accounting services (£5,200 through the charity and £1,000 through Enterprises) (2019: £4,340).
Ashurst LLP, of which N Stalbow is a partner, have provided pro bono services to the value of £26,412 (2019: £58,454).
The aggregated donations made by the trustees were £2,000 (2019: £500).
**----- Start of picture text -----**
13. GRANT COMMITMENTS
**----- End of picture text -----**
Small grants committed at 31 December 2020 were £85,028 (2019: £85,242).
28
~~ANTIBIOTIC RESEARCH UK~~
NOTES
ANTIBIOTIC RESEARCH UK
29
NOTES
ANTIBIOTIC RESEARCH UK
NOTES
ANTIBIOTIC RESEARCH UK
31
~~**Text to . to make a one-time £10 donation**~~
~~**Text to . to make an ongoing donation of £10 per month**~~
~~Please obtain the bill payer’s permission. Age 16+. UK mobile networks only. One off donations charged at £10 + std rate. Monthly subscription donations charged at £10 + std rate each month. Antibiotic Research UK (ANTRUK) is a registered charity in England & Wales (charity no.1157884).~~
**Antibiotic** RESEARCH UK
**FIGHTING ANTIBIOTIC RESISTANCE TODAY AND TOMORROW**
**www.antibioticresearch.org.uk**